Filtered By:
Source: The American Journal of Cardiology
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 715 results found since Jan 2013.
Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study)
It is unknown whether left ventricular hypertrophy (LVH) diagnosis by electrocardiography improves risk stratification in patients with atrial fibrillation (AF). We investigated the prognostic impact of LVH diagnosis by electrocardiography in a large sample of anticoagulated patients with AF included in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Study. We defined electrographic LVH (ECG-LVH) by strain pattern or Cornell voltage (R wave in aVL plus S wave in V3)>2.0 mV (women) or>2.4 mV (men). LVH prevalence was 22.7%. During a median follow-up of 2.0 years, 303 patients developed a stroke, 778 d...
Source: The American Journal of Cardiology - November 25, 2013 Category: Cardiology Authors: Paolo Verdecchia, Gianpaolo Reboldi, Giuseppe Di Pasquale, Giovanni Mazzotta, Giuseppe Ambrosio, Sean Yang, Janice Pogue, Lars Wallentin, Michael D. Ezekowitz, Stuart J. Connolly, Salim Yusuf, RE-LY Study Investigators Tags: Arrhythmias and Conduction Disturbances Source Type: research
Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome
In conclusion, until the results of additional ongoing or planned randomized trials are known, clinicians must continue to rely on expert opinion and their own clinical judgment when treating these patients.
Source: The American Journal of Cardiology - December 16, 2013 Category: Cardiology Authors: Daniel S. Ice, Timothy A. Shapiro, Eric M. Gnall, Peter R. Kowey Tags: Review Source Type: research
30-Year Trends in Patient Characteristics, Treatment Practices, and Long-Term Outcomes of Adults Aged 35 to 54 Years Hospitalized With Acute Myocardial Infarction
The objectives of our population-based study were to describe>3-decade-long trends in the clinical features, treatment practices, and long-term outcomes of young adults aged 35 to 54 years discharged from the hospital after AMI. The study population consisted of 2,142 residents of the Worcester (Massachusetts) metropolitan area who were hospitalized with AMI at all central Massachusetts medical centers during 16 annual periods from 1975 to 2007. Our primarily male study population had an average age of 47 years. Patients hospitalized during the most recent decade (1997 to 2007) under study were more likely to have a hist...
Source: The American Journal of Cardiology - January 15, 2014 Category: Cardiology Authors: Mayra Tisminetzky, David D. McManus, Joel M. Gore, Jorge Yarzebski, Andrew Coles, Darleen Lessard, Robert J. Goldberg Tags: Coronary Artery Disease Source Type: research
Atrial Fibrillation and Heart Failure: A Bad Combination
Atrial fibrillation (AF) and heart failure (HF) commonly coexist and share similar risk factors such as hypertension, increasing age, valvular heart disease, previous ischemic cardiac event, and diabetes mellitus. Individually, AF and HF increase the risk of stroke and death, and the synergistic combination of AF and HF creates a prothrombotic state that results in worse stroke morbidity and mortality than the mere presence of either condition separately.
Source: The American Journal of Cardiology - January 17, 2014 Category: Cardiology Authors: Yee C. Lau, Deirdre A. Lane, Gregory Y.H. Lip Tags: Heart Failure Source Type: research
Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)
Clinical trials have not provided evidence for a role of statin therapy in reducing aortic valve stenosis (AVS) severity in patients with documented AVS. However, whether statin therapy could prevent the onset of AVS is unknown. Our objectives were (1) to compare the incidence rates of AVS among patients treated with high-dose versus usual-dose statin or placebo and (2) to identify clinical risk factors associated with the development of AVS. We conducted post hoc analyses in 23,508 participants from 3 large-scale multicenter atorvastatin randomized blinded clinical trials: Treating to New Targets, the Incremental Decrease...
Source: The American Journal of Cardiology - February 3, 2014 Category: Cardiology Authors: Benoit J. Arsenault, S. Matthijs Boekholdt, Samia Mora, David A. DeMicco, Weihang Bao, Jean-Claude Tardif, Pierre Amarenco, Terje Pedersen, Philip Barter, David D. Waters Tags: Valvular Heart Disease Source Type: research
Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
In conclusion, among patients with PCI, the effect of vorapaxar is consistent with the overall TRACER results. Patients who received a BMS underwent shorter courses of clopidogrel therapy and displayed trends toward greater ischemic benefit from vorapaxar and lesser bleeding risk, compared with patients who received a DES.
Source: The American Journal of Cardiology - June 20, 2014 Category: Cardiology Authors: Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, Philip E. Aylward, Paul W. Armstrong, Frans Van de Werf, Sergio Leonardi, Harvey D. White, Petr Widimsky, Robert A. Harrington, Angel Cequier, Edmond Chen, Yuliya Lokhnygina, Lars Wallentin, John Strony, Ke Tags: Coronary Artery Disease Source Type: research
Relation of Major Depression to Survival After Coronary Artery Bypass Grafting
In conclusion, we found a strong and significant association between depression and long-term survival in patients with established ischemic heart disease who underwent CABG. Depression was also associated with an increased risk for a combination of death or rehospitalization for heart failure, myocardial infarction, or stroke.
Source: The American Journal of Cardiology - June 20, 2014 Category: Cardiology Authors: Malin Stenman, Martin J. Holzmann, Ulrik Sartipy Tags: Coronary Artery Disease Source Type: research
Comparison of Characteristics and Outcomes of Dabigatran versus Warfarin in Hypertensive Patients with Atrial Fibrillation (From the RE-LY® Trial)
Hypertension is frequent among patients with atrial fibrillation (AF) and is an independent risk factor for stroke. The Randomized Evaluation of Long Term Anticoagulant TherapY (RE-LY) trial found dabigatran 110 mg bid (D 110) and 150 mg bid (D 150) non-inferior or superior to warfarin for stroke reduction in patients with AF, with either a reduction (D 110) or similar rates (D150) of major bleeding. Baseline characteristics and outcomes were compared in patients with and without hypertension. The quality of blood pressure control was also assessed.
Source: The American Journal of Cardiology - July 28, 2015 Category: Cardiology Authors: Rangadham Nagarakanti, Lars Wallentin, Herbert Noack, Martina Brueckmann, Paul Reilly, Andreas Clemens, Stuart J. Connolly, Salim Yusuf, Michael D. Ezekowitz Source Type: research
Comparison of Characteristics and Outcomes of Versus in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial)
Hypertension is frequent in patients with atrial fibrillation (AF) and is an independent risk factor for stroke. The Randomized Evaluation of Long Term Anticoagulant TherapY (RE-LY) trial found dabigatran 110 mg (D110) and 150 mg twice daily (D150) noninferior or superior to warfarin for stroke reduction in patients with AF, with either a reduction (D110) or similar rates (D150) of major bleeding. Baseline characteristics and outcomes were compared in patients with and without hypertension. The quality of blood pressure control was also assessed.
Source: The American Journal of Cardiology - July 28, 2015 Category: Cardiology Authors: Rangadham Nagarakanti, Lars Wallentin, Herbert Noack, Martina Brueckmann, Paul Reilly, Andreas Clemens, Stuart J. Connolly, Salim Yusuf, Michael D. Ezekowitz Tags: Arrhythmias and Conduction Disturbances Source Type: research
Diagnosing Paroxysmal Atrial Fibrillation in Patients with Ischemic Strokes and Transient Ischemic Attacks using Echocardiographic Measures of Left Atrium Function
Twenty-five to thirty-five percent of stroke cases are cryptogenic and it has been demonstrated that paroxysmal atrial fibrillation is the causal agent in up to 25% of these incidents. The purpose of this study was to investigate if left atrial (LA) parameters have value for diagnosing paroxysmal AF in ischemic stroke (IS) and transient ischemic attack (TIA) patients. We retrospectively analyzed 219 patients who after acute IS or TIA underwent a transthoracic echocardiographic examination. Patients were designated as paroxysmal AF-patients if they had one or more reported incidents of AF before or after their echocardiographic examination.
Source: The American Journal of Cardiology - October 16, 2015 Category: Cardiology Authors: Kristoffer Grundtvig Skaarup, Hanne Christensen, Nis Høst, Masti Mahdy Mahmoud, Christian Ovesen, Flemming Javier Olsen, Tor Biering-Sørensen Source Type: research
The Quandary of Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease
Compared to patients with normal renal function, the prevalence of atrial fibrillation (AF) in chronic kidney disease (CKD) is increased, as is consequently the stroke prevalence in these patients. This increased risk of stroke in CKD patients is caused not only by the increased prevalence of AF, but also by associated comorbidities, and inherent platelet and vascular dysfunction. Paradoxically, imbalance in the same factors also increases the bleeding risk, imposing a dilemma as to whether anticoagulation should be prescribed or deferred, particularly in patients with end stage renal disease (ESRD), in whom the bleeding d...
Source: The American Journal of Cardiology - November 18, 2015 Category: Cardiology Authors: Shmuel Schwartzenberg, Eli I. Lev, Alik Sagie, Asher Korzets, Ran Kornowski Source Type: research
Drug-coated balloon for in-stent restenosis in high risk patients: Another brick in the wall of the challenging settings for interventionists
Recently Miglionico et al. published in this Journal an interesting prospective observational study regarding 82 high-risk patients with in-stent restenosis of bare metal stent (BMS), n=48 (59%) or drug-eluting stent (DES), n=34 (41%) .1 All patients had at least one of the following high-risk features: history of hemorrhagic stroke or gastrointestinal bleeding, ischemic stroke not longer of 3 months before, need for oral anticoagulation or non-cardiac surgery or recent surgery, chronic inflammatory disease or neoplasm.
Source: The American Journal of Cardiology - March 21, 2016 Category: Cardiology Authors: Dario Buccheri, Davide Piraino, Giuseppe Andolina, Bernardo Cortese Source Type: research
Drug-Coated Balloon for Instent Restenosis in Patients at High Risk: Another Brick in the Wall of the Challenging Settings for Interventionists
Recently, Miglionico et al1 published in this journal an interesting prospective observational study regarding 82 patients at high-risk with instent restenosis of bare-metal stent, n = 48 (59%) or drug-eluting stent (DES), n = 34 (41%). All patients had at least one of the following high-risk features: a history of hemorrhagic stroke or gastrointestinal bleeding, ischemic stroke not longer of 3 months before, need for oral anticoagulation or noncardiac surgery or recent surgery, chronic inflammatory disease, or neoplasm.
Source: The American Journal of Cardiology - March 20, 2016 Category: Cardiology Authors: Dario Bucchei, Davide Piraino, Giuseppe Andolina, Bernardo Cortese Tags: Readers' Comments Source Type: research
Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials)
Obesity is well-established as a major cardiovascular (CV) risk factor. Obesity confers a greater risk for developing atrial fibrillation (AF), but the relation between obesity and established nonvalvular AF for stroke and all-cause death is still unclear. To ascertain the prevalence of overweight and obesity in patients with nonvalvular AF, their influence on adverse events, and the relation with anticoagulation control, we performed this post hoc analysis of the pooled Stroke Prevention using an Oral Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III and V data sets.
Source: The American Journal of Cardiology - April 19, 2016 Category: Cardiology Authors: Marco Proietti, Deirdre A. Lane, Gregory Y.H. Lip Tags: Arrhythmias and Conduction Source Type: research
Meta-Analysis of Anxiety as a Risk for Cardiovascular Disease
We examined the association of anxiety with cardiovascular mortality, major cardiovascular events (defined as the composite of cardiovascular death, stroke, coronary heart disease and heart failure), stroke, coronary heart disease, heart failure and atrial fibrillation.
Source: The American Journal of Cardiology - May 27, 2016 Category: Cardiology Authors: Connor A. Emdin, Ayodele Odutayo, Christopher X. Wong, Jenny Tran, Allan J. Hsiao, Benjamin HM. Hunn Source Type: research
